Blennow, Kaj

Plasma β-amyloid in Alzheimer's disease and vascular disease

Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 626

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 626

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 614

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., et al. (2021) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 607

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease

Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 598

Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report

Arboleda-Velasquez, J. F., Lopera, F., O’Hare, M., Delgado-Tirado, S., Marino, C., Chmielewska, N., Saez-Torres, K. L., Amarnani, D., Schultz, A. P., Sperling, R. A., et al. (2019) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 598

Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice

Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 573

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P., Maruff, P., Skoog, I., et al. (2019) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 570

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 567

A practical guide to immunoassay method validation

Andreasson, U., Perret-Liaudet, A., van Waalwijk van Doorn, L. J. C., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H. B., et al. (2015) · Frontiers in Neurology

Clinical Laboratory Practices and Quality ControlAdvanced Biosensing Techniques and Applications

Cited by 546

A multicentre validation study of the diagnostic value of plasma neurofilament light.

Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., et al. (2021) · Nature Communications

Dementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research

Cited by 545

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

Palmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 524

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine

Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments

Cited by 522

Blood biomarkers for Alzheimer’s disease in clinical practice and trials

Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 522

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., et al. (2023) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 522

Current state of Alzheimer’s fluid biomarkers

Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 518

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 513

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder

Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., et al. (2017) · Neurology

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 506

Plasma tau in Alzheimer disease

Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., et al. (2016) · Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 502

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

Janelidze, S., Teunissen, C. E., Zetterberg, H., Allué, J. A., Sarasa, L., Eichenlaub, U., Bittner, T., Ovod, V., Verberk, I. M. W., Toba, K., et al. (2021) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 494

Microglial activation and tau propagate jointly across Braak stages

Pascoal, T. A., Benedet, A. L., Ashton, N. J., Kang, M. S., Therriault, J., Chamoun, M., Savard, M., Lussier, F. Z., Tissot, C., Karikari, T. K., et al. (2021) · Nature Medicine

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 490

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 487

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

Gisslén, M., Price, R. W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., Fuchs, D., Spudich, S., Blennow, K., & Zetterberg, H. (2016) · EBioMedicine

HIV Research and TreatmentInfectious Diseases and Tuberculosis

Cited by 481

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology

Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and Treatments

Cited by 473